189955-89-3

Upstream product

• 108-88-3 toluene 
• 180048-73-1 2-hydroxy-2-methyl-1-(4-(methylsulfonyl)-phenyl)propan-1-one 
• 13831-31-7 Acetoxyacetyl chloride 
• 300355-18-4 (4-methanesulfonyl-phenyl)-acetic acid methyl ester 
• 62936-31-6 (4-methylsulfanylphenyl)oxoacetic acid ethyl ester 
• 102697-45-0 (4-methylsulfonylphenyl)-2-oxo-acetic acid ethyl ester 
• 88324-55-4 2-bromo-2-methyl-1-[4-(methylsulfanyl)phenyl]propan-1-one 
• 100-68-5 methyl-phenyl-thioether 
• 53207-59-3 2-methyl-1-[4-(methylsulfonyl)phenyl]propan-1-one 
• 49660-93-7 4'-bromoisobutyrophenone 
• 10342-83-3 4'-Bromopropiophenone 
• 71867-98-6 2-hydroxy-2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 
• 53207-58-2 2-methyl-1-(4-(methylthio)phenyl)-propan-1-one 

Downstream Products

• 213833-56-8 5,5-dimethyl-3-(2-methylallyloxy)-4-(4-methylsulfonylphenyl)-5H-furan-2-one 
• 213833-43-3 3-((2-hydroxy-2-methyl-3-butenyl)oxy)-5,5-dimethyl-4-(4-methylsulfonyl)phenyl-5H-furan-2-one 
• 213833-44-4 3-(2-Bromo-1-methylethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-5H-furan-2-one 
• 189954-96-9 3-(Cyclopropylmethoxy)-5.5-dimethyl-4-(4-(methylsulfonyl)phenyl)-5H-furan-2-one 
• 189954-76-5 3-(4-Methyl-5-nitro-2-pyridyloxy)-5,5-dimethyl-4-(4-methylsulfonyl)-phenyl-5H-furan-2-one 
• 189955-97-3 3-(3-Nitro-2-pyridyloxy)-5,5-dimethyl-4-(4-methyl-sulfonyl)phenyl-5H-furan-2-one 
• 213833-47-7 3-(((2R)-3-hydroxy-2-methylpropyl)oxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-5H-furan-2-one 

Relevant academic research and scientific papers

Preparation method of ferocoxib

The invention relates to the technical field of medicines, in particular to a preparation method of ferocoxib. According to the preparation method, use of volatile heavy-odor raw material thioanisoleis avoided, and use of volatile high-corrosion heavy-odor isobutyryl chloride is avoided, so that environmental protection advantages are obvious; a hydroxyl compound is used for preparing a compoundwith a structure shown in a formula VI, so that use of liquid bromine with high volatility, high toxicity and high corrosivity can be avoided; a compound with a structure shown in a formula V, acetoxyacetyl chloride, an alkali and an organic solvent are mixed for carrying out an esterification reaction to obtain a compound with a structure shown in a formula VI, so that use of cyclopropoxy aceticacid which cannot be industrially produced on a scale is avoided, and then the process is easier to popularize. A test result shows that the preparation method of ferocoxib is more green and environmentally friendly, is more suitable for industrial popularization, and is far superior to the prior art.

Method for preparing firocoxib

The invention relates to the technical field of medicines and particularly relates to a method for preparing firocoxib. Raw materials used in the preparation method are conventional reagents in the market, thioanisole which is easily volatized and has str

NEW PROCESS FOR THE SYNTHESIS OF FIROCOXIB

The present invention concerns a process for the preparation of firocoxib, i.e. 3-(cyclopropylmethoxy)-5,5-dimethyl-4-(4-methylsulfonylphenyl)-furan-2-one, comprising steps (a)-(g), wherein the process provides for step (d) of the reaction of a new intermediate, i.e. 2-methyl-1-[4-(methylsulfanyl)phenyl]-1-oxopropan-2-yl (acetyloxy)acetate (compound VII) in the same organic solvent of step (a) in the presence of a catalyst and a phase transfer catalyst solution in the same organic solvent with hydrogen peroxide.

Synthesis method of Firocoxib

The invention relates to a synthesis method of Firocoxib. The synthesis method comprises the steps that a compound A serves as a starting raw material to be condensed with acetoxyacetyl chloride to obtain a compound B; ring closing is conducted under the

Synthesis methods of firocoxib and firocoxib intermediate

The invention relates to the field of medicine synthesis and provides synthesis methods of firocoxib and a firocoxib intermediate. The synthesis method of the firocoxib intermediate takes 4'-bromopropiophenone as a starting raw material and a condition th

(METHYLSULFONYL)PHENYL-2-(5H)-FURANONES WITH OXYGEN LINK AS COX-2 INHIBITORS

The invention encompasses the novel compound of Formula (I) useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising co

(methylsulfonyl)phenyl-2-(5H)-furanones with oxygen link as COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising comp

(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula I useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula I.

(Methylsulfonyl)phenyl-2-(5H)-furanones as COX-2 inhibitors

The invention encompasses the novel compound of Formula A that is useful in the treatment of cyclooxygenase-2 mediated diseases. STR1 The invention also encompasses certain pharmaceutical compositions for treatment of cyclooxygenase-2 mediated diseases comprising compounds of Formula A.

SAR in the alkoxy lactone series: The discovery of DFP, a potent and orally active COX-2 inhibitor

Extensive SAR has been established in the alkoxy lactone series and this has lead to the discovery of DFP (5,5-dimethyl-3-(2-propoxy)-4- methanesulfonylphenyl)-2(5H)-furanone), a potent COX-2 inhibitor exhibiting in vivo efficacy in all models studied.